Reported adverse drug events in infants and children under 2 years of age.
about
Toxic element contamination of natural health products and pharmaceutical preparationsPediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP ProjectSystematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.Pediatric medication errors in the postanesthesia care unit: analysis of MEDMARX data.Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials DataIndividual case safety reports in children in commonly used drug groups - signal detectionMedication use in the neonatal intensive care unitRates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.Information about adverse drug reactions reported in children: a qualitative review of empirical studiesA study of adverse drug reactions in pediatric patients.Dose estimation for children.Adverse drug events in hospitalized children at Ethiopian University Hospital: a prospective observational study.Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus PreventionAn ounce of prevention: a pound of cure for an ailing health care system.Pharmacovigilance in children in Camagüey Province, CubaAdverse drug reactions in neonates and infants: a population-tailored approach is needed.Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.The role of communication in paediatric drug safety.The trials and tribulations of doing drug research in childrenBitter medicine. New regulations aim to address the dearth of clinical safety trials for drugs used in children.Diaspora of clinical medicine: exploring the rift between conventional and alternative health care.Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADRPalivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Where physicians look for information on drug prescribing for children.Prophylaxis of respiratory syncytial virus in Canada in 2003.Reported Adverse Drug Reactions in Infants: A Nationwide Analysis in Malaysia.Adverse effects of antiepileptic drugs: a brief overview of important issues.Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection.Improving the reporting of adverse drug reactions in the hospital setting.Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.Adverse drug reactions in neonates: could we be documenting more?Allergy-like Immediate Reactions with Herbal Medicines in Children: A Retrospective Study Using Data from VigiBase(®).Adverse drug reactions in children: a ten-year review of reporting to the Portuguese Pharmacovigilance System.Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis.Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance databasePaediatric adverse drug reactions can be fatal.Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population.Drugs associated with adverse events in children and adolescents.Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
P2860
Q21133887-F52520B5-4C91-41A6-9D45-26EECACD9DA0Q28548499-2D7171D2-C462-4040-BB59-C6746A2086A8Q30248580-2E52885A-1EE1-40E5-92D9-2D3B9A7A06B7Q31108506-8C29320D-57D1-4460-B63F-907435BCB048Q31137297-91AE9459-13F8-4C39-BF22-C381E3335344Q33325641-6CE4B638-E822-4569-AF87-6A0E03DDFD37Q33769958-40B79C38-08DB-4F8F-AB2F-8C5966DAAF04Q33959735-2311D346-413F-4BD1-B16D-1427713E5B6CQ34180437-CCD45B99-1BAA-4E93-85F2-5E9B19D2DA66Q35411449-C2AB3DF7-4C7F-489C-BA43-B1DDA5609DD5Q35598801-4F3BD1CC-EB7F-45AB-9D80-597E6B39F5EBQ35691131-F4FDDFEE-F7FB-47E3-BAFA-46329BF62487Q35735115-3ED57898-3FEB-4490-8207-19AFF9FF7AD7Q35951342-3769D36B-0798-4F92-997A-4E0CAD064ED4Q36028529-A2278C6D-F4AB-4DD3-B3CD-CF1A3F0A1CC5Q36125509-0BEDAF20-BDC6-4F2C-A5DF-ABF29AD01853Q36125536-FF899617-FA88-4EEE-882C-0B8448E9B747Q36155425-629657A6-7E73-4FB6-B9DF-A9EB473BCB78Q36617686-07991DC4-4C46-485A-8723-3E66277D47A7Q36719334-5616604A-86C3-4992-A0C9-783B24616A9BQ36925992-653AC2FB-6BF5-45C5-8932-E1FAEFEB6046Q37099049-14E48016-368C-4CB3-A4CC-53C8914060AAQ37290618-3DE96432-ADA0-408B-A630-DB684ABA5082Q37473037-A6C7029A-C3B2-4BE7-AD68-A7F43B6024B9Q37481321-04B8A863-D086-4061-AFE6-5B7121A7D335Q37634673-B1DFEC01-CD0E-4A0B-8253-2777A14FEE3BQ37762256-E47E9915-E1EB-4486-A400-42147384D345Q37800514-DFBFCDD5-234F-4400-A41E-E7AAD525CF07Q37810421-41331887-27A4-4E1E-9345-456F0A43CAADQ37868004-1C163C7E-9939-42FF-985D-3B201342FEB1Q37872784-A135C7D8-5798-410B-9961-D86140171745Q38250020-712783C1-2846-4F5D-9FAB-E0F821B99913Q38605891-99130B5B-D7E9-4CEE-A88B-5380DF5B4207Q38628506-2D090521-3BB5-427F-8529-1F6EFACB5BB7Q39420922-017CEE35-F4E0-4249-9EE6-491A119D422CQ41634894-4F828DB6-343E-421B-8945-4C304DDF876BQ42954603-191A2448-D3A9-4B40-A768-2929BD6AC2BDQ44250124-D6CE4B41-DB88-4F67-8A58-C25640B76A53Q44405759-5A51CEF4-C8E7-454C-BEB9-0C84444EC2E7Q45196730-E59FE70E-D0CB-47EE-99AE-E62487A1CBA9
P2860
Reported adverse drug events in infants and children under 2 years of age.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Reported adverse drug events in infants and children under 2 years of age.
@en
Reported adverse drug events in infants and children under 2 years of age.
@nl
type
label
Reported adverse drug events in infants and children under 2 years of age.
@en
Reported adverse drug events in infants and children under 2 years of age.
@nl
prefLabel
Reported adverse drug events in infants and children under 2 years of age.
@en
Reported adverse drug events in infants and children under 2 years of age.
@nl
P2093
P356
P1433
P1476
Reported adverse drug events in infants and children under 2 years of age.
@en
P2093
Carol J Blaisdell
Sheila R Weiss
Sigal Kaplan
Thomas J Moore
P356
10.1542/PEDS.110.5.E53
P407
P577
2002-11-01T00:00:00Z